Welcome to our dedicated page for ARS Pharms SEC filings (Ticker: SPRY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other key documents. ARS Pharma describes itself as a commercial-stage biopharmaceutical company focused on epinephrine nasal spray products for emergency treatment of Type I allergic reactions, including anaphylaxis, and its filings help investors understand how this business is being financed, governed, and developed.
Recent Forms 8-K illustrate several important themes. Some filings report financial results and business updates for specific quarters, where ARS Pharma furnishes press releases discussing revenue from neffy, commercial launch progress, and cash resources. These items fall under “Results of Operations and Financial Condition” and “Regulation FD Disclosure,” and are incorporated by reference to attached exhibits.
Other 8-Ks describe material definitive agreements and financing arrangements, such as the senior secured term loan facility of up to $250 million with affiliates of RA Capital Management and OMERS Life Sciences. These filings outline the structure of the term loans, interest terms, collateral, covenants, and intended use of proceeds, which ARS Pharma states include funding research, development, and commercialization activities for its products, as well as general corporate purposes.
ARS Pharma also uses 8-K filings to disclose legal and intellectual property developments. For example, the company has reported receiving a Paragraph IV certification notice related to a proposed generic version of neffy 2 mg (epinephrine nasal spray) and has stated its intention to pursue patent infringement litigation to defend its listed U.S. patents.
Through Stock Titan, users can track these filings as they are posted to EDGAR and use AI-powered summaries to quickly understand the main points of each document. This includes highlighting where ARS Pharma discusses neffy’s commercialization, financing arrangements, intellectual property strategy, and other material events that may be relevant to shareholders and prospective investors.
ARS Pharmaceuticals insider reported coordinated sales under a 10b5-1 plan. The reporting person, ARS Chief Medical Officer Sarina Tanimoto, sold a total of 50,000 shares in two transactions on 08/19/2025 and 08/20/2025 at weighted average prices of $14.0254 and $14.0914, respectively. Following the sales the filing shows the reporting person has 1,247,447 shares held indirectly via a charitable remainder unitrust and related trusts, and large additional indirect trust holdings are disclosed.
ARS Pharmaceuticals, Inc. (SPRY) filed a Form 144 reporting a proposed sale of 12,500 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $187,500.00. The filing lists 98,826,337 shares outstanding and indicates the approximate date of sale as 08/21/2025 on the NASDAQ.
The securities were acquired on 08/21/2025 by stock option exercise from the issuer, and payment was made in cash on the same date. No other securities sales in the past three months were reported and no additional narrative or signatory details are provided in the filing.
ARS Pharmaceuticals, Inc. (SPRY) filed a Form 144 notifying of a proposed sale of 150,000 shares of common stock through The Charles Schwab Corporation, with an aggregate market value of $2,123,000.00. The form lists approximately 98,826,337 shares outstanding and an approximate sale date of 08/21/2025 on NASDAQ. The shares were acquired on 09/25/2015 as founders and Series A shares from the issuer. The filing also discloses recent sales by Sarina Tanimoto & Richard E Lowenthal of 12,344 shares on 08/19/2025 for $173,129.00 and 37,656 shares on 08/20/2025 for $530,625.00. The notice includes the standard representation regarding absence of undisclosed material adverse information.
ARS Pharmaceuticals (SPRY) filed a Form 144 notifying the proposed sale of 150,000 shares of common stock through The Charles Schwab Corporation at an aggregate market value of $2,100,000. The shares were originally acquired on 09/25/2015 as Founders & Series A shares from the issuer and the filer indicates no securities sold in the past three months. The filing lists approximately 98,826,337 shares outstanding for the company and an approximate planned sale date of 08/19/2025 on NASDAQ. The notice includes the standard representation that the seller does not possess undisclosed material adverse information and references reliance on Rule 10b5-1 procedures where applicable.
ARS Pharmaceuticals is a biopharmaceutical company commercializing neffy, the first FDA- and European Commission-approved needle-free intranasal epinephrine product, which launched commercially in September 2024. For the quarter ended June 30, 2025 the company reported product revenue of $12.8 million and total revenue of $15.7 million, up from $0.5 million in the year-ago quarter due to initial commercial sales and collaboration revenue.
The company reported a net loss of $44.9 million for the quarter and $78.8 million for the six months, driven by operating expenses of $63.3 million in Q2, including $54.3 million of selling, general and administrative costs. As of June 30, 2025 ARS held $51.5 million in cash and $188.6 million in short-term investments (totaling about $240.1 million), which management states is sufficient to meet anticipated cash requirements for at least the next 12 months. Significant collaboration activity includes a $145.0 million upfront from ALK and a $5.0 million milestone earned on first commercial sale in the ALK territory.
ARS Pharmaceuticals, Inc. announced its financial results for the quarter ended June 30, 2025 via a press release attached to this Form 8-K as Exhibit 99.1. The company states that the press release is furnished and expressly not "filed" for purposes of the Exchange Act, and therefore is not incorporated by reference into other filings. The filing also confirms that ARS is an emerging growth company and that its common stock trades on The Nasdaq Stock Market under the symbol SPRY.
The company also updated its corporate investor presentation, which is available on the company website and is attached as Exhibit 99.2. The 8-K repeats that the presentation is furnished and not deemed filed, and lists the exhibits including the Interactive Data File Cover Page as Exhibit 104.
Amendment No. 3 to Schedule 13D discloses that a group of Deerfield-affiliated investment vehicles and their managing partner, James E. Flynn, collectively own 9,724,508 shares of ARS Pharmaceuticals, Inc. ("SPRY"), equal to 9.90 % of the company’s outstanding common stock as of 12 May 2025 (98,213,561 shares).
The filing details ownership across six reporting persons:
- Deerfield Mgmt III, L.P. – 4,862,254 shares (4.95 %)
- Deerfield Private Design Fund III, L.P. – 4.95 %
- Deerfield Mgmt IV, L.P. – 4.95 %
- Deerfield Private Design Fund IV, L.P. – 4.95 %
- Deerfield Management Company, L.P. – 9.90 %
- James E. Flynn – 9.90 %
Recent trading activity: On 27 Jun 2025, Deerfield Private Design Funds III & IV sold a combined 790,149 shares on the Nasdaq Global Market at a weighted-average price of $18.45 (range $18.20–$18.89). No other transactions were reported within the past 60 days.
All voting and dispositive power is reported as shared; none of the entities retains sole power. The amendment principally updates share totals and percentages after the late-June dispositions. Following the sales, Deerfield’s aggregate stake remains just under the 10 % threshold that would otherwise trigger additional reporting or potential Section 16 insider status.
FAQ
What is the current stock price of ARS Pharms (SPRY)?
What is the market cap of ARS Pharms (SPRY)?
